Viveve Geneveve Treatment of the Vaginal Introitus to Evaluate Safety &

Status Completed

Clinical Trial Summary

This study is evaluating the safety and efficacy of the Geneveve Treatment for women experiencing diminished sexual function following vaginal childbirth. Participants will be randomized to either active or sham treatment and followed for 12 months.

Clinical Trial Description

Decreased sensation and decreased sexual satisfaction following vaginal childbirth has the potential to negatively impact overall sexual function and quality of life in many women. Previous research by obstetricians and gynecologists (OB/GYNs) found that changes in sexual health post-childbirth are not often discussed between physicians and their patients. One possible reason these discussions are not being initiated by physicians is the lack of an evidence-based treatment other than surgery.

While traditional surgery can be performed to improve sexual function following childbirth, pain at incision lines and scarring can lead to dyspareunia for months following the procedure, and a surgical procedure can be painful and the sutures may cause dense scarring. The post-operative recovery may last up to seven days before a woman can return to work. Resuming intercourse is not recommended for at least six weeks after these invasive surgeries. For the many women who are not good surgical candidates, due to health issues or situational limitations on downtime or their unwillingness to undergo a surgical procedure to improve sexual function, there is no other option.

The Geneveve Treatment offers a simple alternative to traditional surgery using non-ablative radiofrequency (RF) energy as a non-surgical approach to improve sexual function following vaginal childbirth. It induces a mild, controlled reaction in the submucosal tissues that stimulates the body to deposit collagen, thereby remodeling the tissue without causing scarring.

This study is designed to demonstrate that active treatment (i.e., Geneveve Treatment) is superior to the sham treatment for the primary efficacy and safety endpoints.

The active treatment group will receive a treatment dose of 90 J/cm^2 and the sham group will receive a sub-therapeutic dose of ≤ 1 J/cm^2. The participant, the investigator, and all study personnel will be blinded to the assignment for the entire study duration. ;

Study Design

Related Conditions & MeSH terms

Female Sexual Dysfunction

Clinical Trial Details

NCT number	NCT03479229
Study type	Interventional
Source	Viveve Inc.
Contact
Status	Completed
Phase	N/A
Start date	April 20, 2018
Completion date	March 15, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05806424` - Investigation of Awareness Levels of Women Living in Turkey About Kegel Exercises and Pelvic Floor Muscles
Completed	`NCT01364623` - PK Study of Testosterone Nasal Gel (TBS-2) in Healthy Premenopausal Women	Phase 1
Recruiting	`NCT06060691` - the Ameliorating Effects of Antioxidant Gel on Female Arousal Disorder and Sexual Dysfunction	Phase 1
Recruiting	`NCT04419961` - Sexual Dysfunction and an Educational Program to Improve the Quality of Sexual Function in Vietnamese Pregnant Women in First Trimester	N/A
Completed	`NCT04122703` - Trial of Tibial Nerve Stimulation for Treating Sexual Dysfunction	N/A
Recruiting	`NCT03498443` - Effect of Pelvic Organ Prolapse Surgeries on Female Sexual Function in Egyptian Women
Completed	`NCT03232801` - A Mindfulness-based Intervention for Older Women With Low Sexual Desire	N/A
Completed	`NCT04124640` - Observational Study in Real Life to Describe the Libicare® Effectiveness in Female Sexual Dysfunction.
Completed	`NCT00995072` - Comparative Effects of Nebivolol and Metoprolol on Female Sexual Function	N/A
Active, not recruiting	`NCT05168371` - Cognitive-Behavioural & Mindfulness-Based Online Programs for Female Sexual Dysfunction	N/A
Recruiting	`NCT04384172` - Effect of Peripheral Neuromodulation on Vaginal Blood Flow	N/A
Completed	`NCT03463707` - BP101 for Adults With Female Sexual Dysfunction	Phase 3
Recruiting	`NCT01078077` - The Impact of a Topical Vasodilating Cream on Female Sexual Experience	N/A
Not yet recruiting	`NCT06237166` - Evaluation of an Online Intervention for Female Sexual Dysfunction	N/A
Completed	`NCT02229721` - Effect of Chronic Intranasal Oxytocin Administration on Sexual Function in Pre- and Postmenopausal Women	Phase 2
Completed	`NCT01724658` - Effectiveness of Testosterone Undecanoate to Improve Sexual Function in Postmenopausal Women	Phase 2
Completed	`NCT00479570` - Study To Investigate Effect Of A New Drug (PF-00446687) In Post-Menopausal Women Who Suffer From Sexual Dysfunction.	Phase 2
Withdrawn	`NCT02862184` - Female Sexual Dysfunction, Risks and Outcomes (FSFI)	N/A
Completed	`NCT01195701` - Clitoral Location in Relation to Sexual Function Using Pelvic Imaging	N/A
Completed	`NCT04484753` - Validation of iPelvis App for Female Pelvic Floor Dysfunction	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Viveve Geneveve Treatment of the Vaginal Introitus to Evaluate Safety and Efficacy — VIVEVE II

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms